Molecular imaging exploration of ocular angiogenic activity and evaluation of its value in therapeutic follow-up of AMD patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516970-31-00

Enrollment

Registered

2024-10-17

Start date

2022-10-02

Completion date

2025-01-04

Last updated

2024-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Brief summary

The PET signal intensity ratios (SUVmax) of the AMD and contralateral eyes at M0 and M4 will be compared by a paired means comparison test.

Detailed description

The relationships between PET signal intensity (SUVmax) and retinal thickness measured by OCT, for each eye, will be documented at M0 and M4 respectively by a correlation study., The links between PET signal intensity (SUVmax) and the visual acuity score measured with each of the psychometric scales (ETDRS and Parinaud), for each eye, will be documented at M0 and M4 respectively by a correlation study.

Interventions

DRUG68Ga-RGD 15MBq/mL prep

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The PET signal intensity ratios (SUVmax) of the AMD and contralateral eyes at M0 and M4 will be compared by a paired means comparison test.	—

Secondary

Measure	Time frame
The relationships between PET signal intensity (SUVmax) and retinal thickness measured by OCT, for each eye, will be documented at M0 and M4 respectively by a correlation study., The links between PET signal intensity (SUVmax) and the visual acuity score measured with each of the psychometric scales (ETDRS and Parinaud), for each eye, will be documented at M0 and M4 respectively by a correlation study.	—

Measure

Time frame

—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026